Moyamoya Disease Market Research Report - Global Forecast till 2023

Moyamoya Disease Market Information: By Diagnosis (Cerebral Angiogram, MRI, MRA, CT Scan, Transcranial Doppler Ultrasound, PET Scan, Electroencephalography), Treatment (Surgical, Non-Surgical Treatment), Distribution Channel – Global Forecast till 2023

Market Scenario
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and seizures.

According to the National Organization for Rare Diseases, in Japan, moyamoya disease is estimated to occur in 1 per 1 million people, and the condition is more prevalent in females under the age of 20. It is also reported that nearly 10% of cases of moyamoya disease in Asian countries have a genetic cause. Recently, two major mutations have been found to be associated with a specific population of moyamoya patients i.e. R179, and RNF213 mutations.

Intended Audience
- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Diagnostic Laboratories
- Government Research Institute
- Academic Institutes and Universities

Key Players

Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation

It is noted that growing public awareness and technological advancements are the key factors driving the moyamoya disease market. Nowadays, people are becoming more aware of different types of neurological disorders. Government and other different organizations have started educating people about hygiene and diseases through seminars, and conferences. People are becoming more aware and health conscious. Thus, increasing awareness has provided a push to the growth of the market. The new and existing marketers are also contributing to control this condition. For instance, on April 13, 2016, Silk Road Medical, Inc., received FDA approval for its next-generation ENROUTE Transcarotid Neuroprotection System (NPS). The NPS is specifically designed and indicated for transcarotid artery revascularization.

Various other factors such as increased incidence of neurological disorders, unmet medical needs, increasing government assistance, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement are continuously contributing to the growth of the global moyamoya disease market.

Despite these drivers, there are some issues associated with moyamoya disease market. The challenges in research and development, cost of treatment, side-effects of treatment, the presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, may hinder the growth of the market to an extent.

It is estimated that the moyamoya disease market is expected to grow at a CAGR 7.0% during the forecast period of 2017-2023.

Segmentation

The global moyamoya disease market is segmented on the basis of diagnosis, treatment, and distribution channels.

On the basis of the diagnosis, the market is classified as a cerebral angiogram, magnetic resonance imaging (MRI), magnetic resonance angiogram (MRA), computed tomography (CT) scans, transcranial Doppler ultrasound, positron emission tomography (PET) scan, and electroencephalography (EEG).

On the basis of the treatment, the market is classified as surgical treatment and non-surgical treatment. The surgical treatment is further classified as pial synangiosis, indirect procedures, and direct arterial bypass. The sub-segment of indirect procedures includes EDAS (encephaloduroarteriosynangiosis), EMS (encephalomyosynangiosis), Omental transposition/transfer, and dural inversion. The non-surgical treatment is further classified as anticoagulation and antiplatelet therapy, and others. The sub-segment of anticoagulation and antiplatelet therapy include heparin, warfarin, aspirin, and others.
On the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies and others.

Regional Analysis

The Americas dominate the moyamoya disease market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Europe holds the second position in the moyamoya disease market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive European market.

The Asia Pacific is the fastest growing moyamoya disease market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.

The Middle East & Africa holds the lowest share of the global market due to lack of technical knowledge and poor medical facilities.

Contents:

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction
  2.1 Definition
  2.2 Scope of the Study
  2.2.1 Research Objective
  2.2.2 Assumptions
  2.2.3 Limitations

Chapter 3. Research Methodology
  3.1 Introduction
  3.2 Primary Research
  3.3 Secondary research
  3.4 Market Size Estimation

Chapter 4. Market Dynamics
  4.1 Drivers
  4.2 Restrains
  4.3 Opportunities
  4.4 Challenges
  4.5 Macroeconomic Indicators
  4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis
  5.1 Porter’s Five Forces Analysis
    5.1.1 Bargaining Power of Suppliers
    5.1.2 Bargaining Power of Buyers
    5.1.3 Threat of New Entrants
    5.1.4 Threat of Substitutes
    5.1.5 Intensity of Rivalry
  5.2 Value Chain Analysis
  5.3 Investment Feasibility Analysis
  5.4 Pricing Analysis

Chapter 6. Global Moyamoya Market, by Diagnosis
6.1 Introduction
6.2 Cerebral Angiogram
6.2.1 Market Estimates & Forecast, 2016 – 2023
6.3 Magnetic Resonance Imaging (MRI)
6.3.1 Market Estimates & Forecast, 2016 – 2023
6.4 Magnetic Resonance Angiogram (MRA)
6.4.1 Market Estimates & Forecast, 2016 – 2023
6.5 Computed Tomography (CT) Scans
6.5.1 Market Estimates & Forecast, 2016 – 2023
6.6 Transcranial Doppler Ultrasound
6.6.1 Market Estimates & Forecast, 2016 – 2023
6.7 Positron Emission Tomography (PET) Scan
6.7.1 Market Estimates & Forecast, 2016 – 2023
6.8 Electroencephalography (EEG)

Chapter 7. Global Moyamoya Market, by Treatment
7.1 Introduction
7.2 Surgical Treatment
7.2.1 Market Estimates & Forecast, 2017 – 2023
7.3 Non-Surgical Treatment
7.3.1 Market Estimates & Forecast, 2017 – 2023

Chapter 8. Global Moyamoya Market, by Distribution Channel
8.1 Introduction
8.2 Hospitals
8.2.1 Market Estimates & Forecast, 2017 – 2023
8.3 Clinics
8.3.1 Market Estimates & Forecast, 2017 – 2023
8.4 Diagnostic Centers
8.4.1 Market Estimates & Forecast, 2017 – 2023
8.5 Drug Stores
8.5.1 Market Estimates & Forecast, 2017 – 2023
8.6 Pharmacies
8.6.1 Market Estimates & Forecast, 2017 – 2023
8.7 Others
8.7.1 Market Estimates & Forecast, 2017 – 2023

Chapter 9. Global Moyamoya Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 U.S.
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 U.K
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
  9.4.1 Japan
  9.4.2 China
  9.4.3 India
  9.4.4 Australia
  9.4.5 Republic of Korea
  9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
  9.5.1 United Arab Emirates
  9.5.2 Saudi Arabia
  9.5.3 Oman
  9.5.4 Kuwait
  9.5.5 Qatar
  9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape
  10.1 Introduction
  10.2 Market Share Analysis
  10.3 Key Development & Strategies
    10.3.1 Key Developments

Chapter 11 Company Profiles
  11.1 Abbott Laboratories
    11.1.1 Company Overview
    11.1.2 Diagnosis of Causative Agents Overview
    11.1.3 Financials
    11.1.4 SWOT Analysis
  11.2 Boston Scientific Corporation
    11.2.1 Company Overview
    11.2.2 Diagnosis of Causative Agents Overview
    11.2.3 Financial Overview
    11.2.4 Key Developments
    11.2.5 SWOT Analysis
  11.3 Cephalon, Inc.
    11.3.1 Company Overview
    11.3.2 Diagnosis of Causative Agents Overview
    11.3.3 Financial Overview
    11.3.4 Key Development
    11.3.5 SWOT Analysis
  11.4 Cordis Corporation, Inc.
    11.4.1 Company Overview
    11.4.2 Diagnosis of Causative Agents/Business Segment Overview
    11.4.3 Financial Overview
    11.4.4 Key Development
    11.4.5 SWOT Analysis
  11.5 Eisai Co., Ltd
    11.5.1 Company Overview
11.5.2 Diagnosis of Causative Agents Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 GE Healthcare
11.6.1 Company Overview
11.6.2 Diagnosis of Causative Agents Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 GENENTECH INC.
11.7.1 Overview
11.7.2 Diagnosis of Causative Agents Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Others

Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Moyamoya Industry

Chapter 13 Appendix

LIST OF TABLES
Table 1 Moyamoya Industry Synopsis, 2017 – 2023
Table 2 Moyamoya Market Estimates and Forecast, 2017 – 2023, (USD Million)
Table 3 Moyamoya Market by Region, 2017 – 2023, (USD Million)
Table 4 Moyamoya Market by Diagnosis, 2017 – 2023, (USD Million)
Table 5 Moyamoya Market by Treatment, 2017 – 2023, (USD Million)
Table 6 Moyamoya Market by Distribution Channels, 2017 – 2023, (USD Million)
Table 7 North America Moyamoya Market by Diagnosis, 2017 – 2023, (USD Million)
Table 8 North America Moyamoya Market by Treatment, 2017 – 2023, (USD Million)
Table 9 North America Moyamoya Market by Distribution Channels, 2017 – 2023, (USD Million)
Table 10 US Moyamoya Market by Diagnosis, 2017 – 2023, (USD Million)
Table 11 US Moyamoya Market by Treatment, 2017 – 2023, (USD Million)
Table 12 US Moyamoya Market by Distribution Channels, 2017 – 2023, (USD Million)
Table 13 Canada Moyamoya market by Diagnosis, 2017 – 2023, (USD Million)
Table 14 Canada Moyamoya Market by Treatment, 2017 – 2023, (USD Million)
Table 15 Canada Moyamoya market by Distribution Channels, 2017 – 2023, (USD Million)
Table 16 South America Moyamoya Market by Diagnosis, 2017 – 2023, (USD Million)
Table 17 South America Moyamoya Market by Treatment, 2017 – 2023, (USD Million)
Table 18 South America Moyamoya Market by Distribution Channels, 2017 – 2023, (USD Million)
Table 19 Europe Moyamoya Market by Diagnosis, 2017 – 2023, (USD Million)
Table 20 Europe Moyamoya Market by Treatment, 2017 – 2023, (USD Million)
Table 21 Europe Moyamoya Market by Distribution Channels, 2017 – 2023, (USD Million)
Table 22 Western Europe Moyamoya Market by Diagnosis, 2017 – 2023, (USD Million)
Table 23 Western Europe Moyamoya Market by Treatment, 2017 – 2023, (USD Million)
Table 24 Western Europe Moyamoya Market by Distribution Channels, 2017 – 2023, (USD Million)
Table 25 Eastern Europe Moyamoya market by Diagnosis, 2017 – 2023, (USD Million)